SHINE Technologies is a next-generation fusion technology company headquartered in Janesville, Wisconsin. Their proprietary isotope production processes create n.c.a. lutetium-177 (Lu-177), crucial for therapeutic medical procedures. SHINE is producing and shipping n.c.a. Lu-177, with a Drug Master File established with the U.S. Food and Drug Administration. SHINE is expected to produce up to 200,000 doses per year. Learn more at https://www.shinefusion.com/ and @shinefusion.